Newly unveiled results from Edwards Lifesciences (NYSE:EW) transcatheter aortic valve studies showed mixed results for its Sapien TAVI system when compared with surgical aortic valve replacement.
Edwards Lifesciences
TAVI: Medtronic’s next-gen Engager looks good in 1st pivotal study results
Heart valves: Three-year Sapien data buoy Edwards Lifesciences
Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter aortic valve implantation system, the only TAVI device on the U.S. market, demonstrated sustained and increasing survival benefits out to 3 years among inoperable heart failure patients, according to newly unveiled study results.
TAVI at TCT 2012: Climbing the learning curve and making way for improvement
Edwards wins extended Sapien TAVI approval, sinks on disappointing Q3
Edwards Lifesciences (NYSE:EW) won FDA approval to market its Sapien transcatheter aortic valve implantation system to lower-risk patients, despite concerns about limited patient data on the long-term side effects of the device.
Breaking: FDA approves Edwards’ Sapien TAVI system for lower-risk patients
Edwards Lifesciences (NYSE:EW) won FDA approval to market its Sapien transcatheter aortic valve implantation to lower-risk patients, despite concerns about limited patient data on the long-term side effects of the device.
Edwards Lifesciences closes $42M buyout of Dutch hemo monitoring company
Edwards Lifesciences (NYSE:EW) won some Wall Street love after it closed the books on a $42 million buyout of privately held Dutch hemodynamic monitoring technology company BMEYE B.V.
Heart valves: Edwards Lifesciences, Medtronic to face stiffer competition
It’s not your father’s transcatheter aortic valve implant anymore.
Next year and the year after, the competitive landscape for TAVI will explode, with as many as 12 competing devices on the market here and across the pond.
And that competition will be fierce. As TAVI celebrates its 10th birthday,at least 1 analyst is predicting a 20%+ compound annual growth rate for the market, which she says could potentially double by 2015.
Edwards Lifesciences loses 19% on lower Q3 outlook
The European debt crisis, a delayed reimbursement decision and summer vacations conspired to reduce expected 3rd-quarter sales for Edwards Lifesciences (NYSE:EW), sending its share price plunging on Wall Street.
TAVI pioneers celebrate 10 years and more than 50,000 patients treated
The 1st transcatheter aortic valve was implanted 10 years ago, laying the foundation for a game-changing technology that has since matured "from an ugly duckling into a beautiful swan," according one researcher.
TAVI global registry delivers 1st results | MassDevice.com On Call
Updated October 3, 2012, at 9:45 p.m. to correct the lead story.
MASSDEVICE ON CALL — The 1st reports from a global registry evaluating Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter aortic valve implantation inside a failing valve or mitral ring came with mixed results.*